Mouse and cell study: IL-17A linked to chondrocyte senescence in TMJ osteoarthritis
In mice with experimentally induced temporomandibular joint osteoarthritis and in cultured mouse chondrocytes, IL-17A was associated with chondrocyte senescence; blocking IL-17A with secukinumab reduced senescence and pathological progression in the mice. This is preclinical evidence, not proof of benefit in people. [1]
Automatic summary · not editorially reviewed
The key findings
In condylar cartilage of TMJ-OA mice, chondrocyte senescence correlated positively with IL-17A expression, and IL-17A induced senescence in cultured ATDC5 mouse chondrocytes. [1]
The authors propose that IL-17A raises STAT3 phosphorylation, increasing OPA1 expression, causing mitochondrial hyperfusion and more mtROS, linked to mitochondrial dysfunction and senescence. [1]
In TMJ-OA mice, secukinumab reduced chondrocyte senescence and inhibited pathological progression; the authors suggest IL-17A as a therapeutic target. [1]
The source at a glance
- Study type / format
- Preclinical animal and in vitro cell study (abstract).
- Population / context
- Mice with unilateral anterior crossbite-induced TMJ-OA and cultured ATDC5 mouse chondrocytes.
- Summary based on
- Study abstract
- Original publication
- September 30, 2026
IL-17A and senescence in TMJ-OA mice and cells
The authors asked how interleukin-17A (IL-17A) might drive chondrocyte senescence in temporomandibular joint osteoarthritis (TMJ-OA). They used a mouse model with unilateral anterior crossbite (UAC) and cultured ATDC5 mouse chondrocytes exposed to IL-17A. In the condylar cartilage of the TMJ-OA mice, chondrocyte senescence correlated positively with IL-17A expression. In the cultured cells, IL-17A induced cellular senescence. These are associations and laboratory observations; the abstract does not report human data.
Supporting source [1]
Proposed STAT3-OPA1-mtROS mechanism in cultured chondrocytes
Mechanistically, the authors report that IL-17A raised the phosphorylation level of signal transducer and activator of transcription 3 (STAT3). This increased expression of optic atrophy 1 (OPA1), a protein involved in mitochondrial fusion. The result was mitochondrial hyperfusion and more mitochondrial reactive oxygen species (mtROS), which the authors link to mitochondrial dysfunction and cellular senescence. These mechanism findings come from cell experiments; the abstract does not show that the same chain operates in human joints.
Supporting source [1]
Secukinumab reduced senescence and progression in TMJ-OA mice
The authors then tested secukinumab, an anti-IL-17A monoclonal antibody, in the TMJ-OA mice. It reduced chondrocyte senescence and inhibited pathological progression. The authors conclude that IL-17A may be a therapeutic target for TMJ-OA. This is preclinical evidence in mice and cells; the abstract does not report a human trial, dosing for people or confirmed clinical benefit.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Findings come from a mouse model and cultured mouse cells, so they are preclinical and do not establish benefit or safety in people.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Zhu M, Zhang C, Zhang Y, Zhang C, Wu Z, Wang Y, Qu L, Wu M, Shen M, Chen Q, Shi J. · europepmc.org · September 30, 2026